154 related articles for article (PubMed ID: 34656365)
1. Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications.
Pestana RC; Roszik J; Groisberg R; Sen S; Van Tine BA; Conley AP; Subbiah V
Curr Probl Cancer; 2021 Oct; 45(5):100794. PubMed ID: 34656365
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
[TBL] [Abstract][Full Text] [Related]
3. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
4. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.
Conley AP; Wang WL; Livingston JA; Ravi V; Tsai JW; Ali A; Ingram DR; Lowery CD; Roland CL; Somaiah N; Hwu P; Yee C; Subbiah V; Futreal A; Lazar AJ; Patel S; Roszik J
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31096717
[TBL] [Abstract][Full Text] [Related]
5. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
6. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
7. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
J Clin Oncol; 2020 Jul; 38(19):2178-2186. PubMed ID: 32421444
[TBL] [Abstract][Full Text] [Related]
9. Identification of Subtype-Specific Metastasis-Related Genetic Signatures in Sarcoma.
Li YL; Gao YL; Niu XL; Wu YT; Du YM; Tang MS; Li JY; Guan XH; Song B
Front Oncol; 2020; 10():544956. PubMed ID: 33123466
[No Abstract] [Full Text] [Related]
10. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.
Hasan NM; Sharma A; Ruzgar NM; Deshpande H; Olino K; Khan S; Ahuja N
Oncotarget; 2021 Aug; 12(16):1566-1579. PubMed ID: 34381562
[TBL] [Abstract][Full Text] [Related]
11. Overview of malignant soft-tissue sarcomas of the limbs.
Renn A; Adejolu M; Messiou C; Bhaludin B; Strauss DC; Thway K; Moskovic E
Clin Radiol; 2021 Dec; 76(12):940.e1-940.e16. PubMed ID: 34607656
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cancer Treat Rev; 2020 Jan; 82():101934. PubMed ID: 31794912
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
14. The rare primary bone sarcomas: imaging-pathological correlation.
Berkeley R; Andrei V; Saifuddin A
Skeletal Radiol; 2021 Aug; 50(8):1491-1511. PubMed ID: 33410967
[TBL] [Abstract][Full Text] [Related]
15. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
16. Loss of Expression of a Novel Chromatin Remodeler SMARCA1 in Soft Tissue Sarcoma.
Patil PA; Lombardo K; Sturtevant A; Mangray S; Yakirevich E
J Cytol Histol; 2018; 9(6):. PubMed ID: 31093468
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
18. Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas.
Song MJ; Cho KJ; Lee JS; Song JS
Appl Immunohistochem Mol Morphol; 2017; 25(10):712-719. PubMed ID: 27028243
[TBL] [Abstract][Full Text] [Related]
19. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer.
Schettini F; Barbao P; Brasó-Maristany F; Galván P; Martínez D; Paré L; De Placido S; Prat A; Guedan S
ESMO Open; 2021 Jun; 6(3):100102. PubMed ID: 33838601
[TBL] [Abstract][Full Text] [Related]
20. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.
Cao YJ; Wang X; Wang Z; Zhao L; Li S; Zhang Z; Wei X; Yun H; Choi SH; Liu Z; Zhao L; Kazane SA
ACS Synth Biol; 2021 May; 10(5):1176-1183. PubMed ID: 33856201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
